RxDoctor Payments DataLook up a doctor →

Richard Kim, MD

Cardiovascular Disease · Delray Beach, FLNPI 1306821350

Payments from drug & device makers

$1,931,302in general payments, 2019–2025

Across 729 payments — averaging $2649.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.1M
  • AstraZeneca$511K
  • Bayer$131K
  • EMD Serono, Inc.$84K
  • Pfizer$51K
  • Astrazeneca UK Limited$14K
  • plus $41K from 42 others
$1,426in research payments, 2019–2025

Across 10 payments — averaging $142.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • EMD Serono, Inc.$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck12$1,099,526
AstraZeneca20$511,083
Bayer50$130,612
EMD Serono, Inc.27$84,022
Pfizer26$50,567
Astrazeneca UK Limited10$14,121
Novartis114$5,324
Atricure, Inc.41$4,237
Exelixis Inc.2$3,960
Abiomed45$3,379
Abbott36$3,161
Elutia, Inc.50$3,096
Penumbra, Inc.24$3,024
Astrazeneca AB1$2,200
Boston Scientific27$1,885
Heartflow, Inc.23$1,731
Medtronic(2 entities)18$1,167
Shockwave Medical, Inc25$1,039
Genentech USA, Inc.4$1,036
Cardiovascular Systems Inc.8$692
Edwards Lifesciences6$676
Amgen29$568
Seagen Inc.1$550
E.r. Squibb & Sons, L.L.C.31$490
Johnson & Johnson15$454
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)17$283
Boehringer Ingelheim10$234
Intera Oncology, Inc1$232
Ipsen Biopharmaceuticals, Inc3$224
Amarin Pharma, Inc.7$205
Cardiva Medical, Inc.6$199
Terumo Medical Corporation2$189
Sanofi-aventis U.S. LLC6$144
Trisalus Life Sciences, Inc.1$140
Chiesi USA, Inc.9$138
Alnylam Pharmaceuticals Inc.6$128
Cardinal Health 200 LLC1$116
Kestra Medical Technology Services, Inc.2$90
Philips North America LLC1$82
BD2$68
Agepha Pharma FZ LLC2$41
Bard Peripheral Vascular, Inc.1$40
Kiniksa Pharmaceuticals International, PLC1$40
Cvrx, Inc.2$26
Bridgebio Pharma, Inc.1$26
Osprey Medical Inc1$26
Biosense Webster, Inc.1$21
Getinge USA Sales, LLC1$12

How this compares

$1,931,302 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida →

Medicare billing

Part B allowed, 2024
$343,203
Medicare patients
1,080
Services billed
4,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Delray Beach

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →